J. Herzog, J. B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, J. Gomez, A. Yovine, B. J. Monk;
Columbia University Medical Center, New York, NY; University Hospital Antwerp, Antwerp, Belgium; Hopital Hotel-Dieu, Paris, France; Johnson & Johnson PRD, USA, Raritan, NJ; PharmaMar SAU, Colmenar Viejo, Madrid, Spain;
University of California Irvine Medical Center, Orange, CA
- Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the OVA-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD (Abstract 5551)
General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C
Authors: A. Poveda, S. B. Kaye, R. T. McCormack, S. Wang, D. Ricci, E. Broderick, T. Parekh, C. Lebedinsky, J. C. Tecero, B. J. Monk; Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Research & Development, Raritan, NJ; PharmaMar SAU, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
- Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625)
General Poster Session, Monday June 1, 8:00 am to 12:00 pm, Level 2, West Hall C
Authors: J. A. Berlin, P. J. Bowers, S. Rao, S. Sun, K. Liu, D. H. Henry; Johnson & Johnson PRD, Titusville, NJ; Johnson & Johnson PRD, Raritan, NJ; Pennsylvania Onc Hem Assoc, Philadelphia, PA
- Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vers
'/>"/>
SOURCE Centocor Ortho Biotech Products, L.P. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor2.
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA3.
Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 20114.
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis5.
Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product6.
GeneNews provides Centocor access to its osteoarthritis program7.
Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)8.
Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients9.
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases10.
New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product11.
Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System